and 40 minutes, 20.4 ± 1.4 (S.E.; n = 5) and 38.6 ± 2.8 (S.E.; n = 5) percent of the $^{14}$C had been released from the choroid plexuses. Moreover, when 1.0 μM FA was placed in the second medium, $^{14}$C release at 20 and 40 minutes increased to 28.0 ± 3.4 (S.E.; n = 4) and 45.5 ± 1.0 (S.E.; n = 4) ($P < .05$). Moreover, when the second medium was kept at 1°C (without FA), only 15.7 ± 3.9 (S.E.; n = 3) was released after 40 minutes ($P < .05$). Thus, a significant portion of the $^{14}$C was not irreversibly bound inside the choroid plexuses.

In conclusion, we have demonstrated in the choroid plexus a specific, saturable uptake system for folates that is distinct from the weak carboxylic acid, weak basic, and ascorbate transport systems of the choroid plexus (9, 14). That is, substances that completely saturated these systems had no effect on folate uptake. The affinity for the folate transport system is: FA > $(±)$- MTHF = $(±)$- MTHF > methotrexate. Evidence in favor of the choroid plexus being a locus of folate transport from blood to CSF would include: (i) The observation that the $K_i$ (18.0 nM) for MTHF in the isolated choroid plexus (that is, the concentration of MTHF at which the uptake system is half-saturated) was approximately that of the blood (1). Moreover, this value was not significantly different from the $K_i$ (12 nM) observed for folate transport from blood into human CSF (6). Thus, a slight increase in the concentration in the plasma would readily saturate folate entry into CSF as observed in vivo (6). The ascorbate transport system from blood to CSF is similar (10). (ii) The finding that, although there was significant intracellular binding of MTHF inside the choroid plexus, there was ready release of intracellular MTHF, a release that was decreased by incubation in the cold. However, questions as to whether reduced folates enter brain primarily from CSF via the choroid plexus rather than directly from blood need to be postponed until this folate transport system in the choroid plexus can be conclusively shown to transport reduced folates in significant amounts from blood to CSF in vivo.

REYNOLD SPECTOR  
A. V. LORENZO  
Department of Neurology,  
Children's Hospital Medical Center,  
Boston, Massachusetts 02115

References and Notes


7. A saturable uptake and release system for folates in the isolated hog choroid plexus has been reported [C. P. Chen and C. Wagner, Fed. Proc. 33, 716 (1974)].

8. The fresh liver was processed without conjugase as suggested by O. D. Bird, V. M. Glibon, and J. W. Vaitkus [Anal. Biochem. 12, 18 (1965)]. The supernatant, to which was added 10 ng of [14C]MTHF, was put through a DEAE-Sephaex column, and the [14C]MTHF was separated from the phosphate on Sephadex G-15 [P. F. Nixon and J. R. Bertino, in Vitamins and Coenzymes, D. B. McCormick and L. D. Wright, Eds. (Academic Press, New York, 1971), p. 661]. The [14C]MTHF was concentrated ten times and chromatographed in two systems (II) and found to be 90 percent pure.

9. A. V. Lorenzo and R. Spector, J. Pharmacol. Exp. Ther. 184, 465 (1973); R. Spector and A. V. Lorenzo, ibid. 188, 55 (1974). The T/M ratios were calculated by dividing the number of curies per milliliter of intracellular H by the number of curies per milliliter of medium.


11. J. P. Brown, G. E. Davidson, J. M. Scott, J. Chromatogr. 79, 195 (1973). The two systems were (i) 0.1M potassium phosphate buffer, pH 6, with 0.5 percent mercaptoethanol and (ii) 3 percent NH4Cl (weight to volume), pH 6.2, with 0.5 percent mercaptoethanol. Thin-layer cellulose plates, 0.1 mm thick, were used (Brinkmann MN 300 UV254).

12. V. Herbert and J. R. Bertino, in The Vitamins, P. Gyorgy and W. N. Pearson, Eds. (Academic Press, New York, 1967), vol. 7, p. 251. We used 0.1M potassium phosphate buffer, pH 6, with 0.5 percent mercaptoethanol.


16. Supported in part by NIH grants NS-HD 0904, NS-05172, and the Children's Hospital Medical Center Mental Retardation and Human Developmental Research Program grant HD 03773. A portion of this work was performed at the Department of Medicine, Peter Bent Brigham Hospital, Boston, Mass. (2115).

20 April 1974; revised 2 July 1974

Toxicology and Pharmacological Action of Anabaena flos-aquae Toxin

Abstract. Calves, rats, ducks, and goldfish given lethal oral doses of bacteria-free lyophilized cell suspensions of toxic Anabaena flos-aquae died as a result of respiratory arrest. Experiments with selected animals and pharmacological preparations showed that the main effect of the toxin was production of a sustained postsynaptic depolarizing neuromuscular blockade.

Algal poisonings, caused by toxic blooms of the blue-green alga Anabaena flos-aquae (Lyngb.) de Bréb., have been an infrequent but repeated occurrence in several countries of the world (1). Most economic loss has been confined to livestock and waterfowl that have drunk wind-concentrated surface blooms, dominated by toxic strains of this alga, which develop in eutrophic freshwater lakes and sloughs during the summer months.

We have studied the toxic effects of lyophilized cells in calves, rats, mice, ducks, and goldfish and have also investigated the mechanism of action of toxin extracts of the algae. Bacteria-free cultures of A. flos-aquae NRC-44-1 were used (2). Mass cultures were concentrated by flash evaporation and lyophilized. Aqueous suspensions of lyophilized cells from different batches of the alga had a consistent minimum lethal dose (MLD) of 60 mg kg⁻¹ administered intraperitoneally when bioassayed on male mice (15 to 23 g) or male rats (300 to 400 g).

A toxin extract was prepared from the lyophilized cells by a modification of the procedure of Stavric and Gorman (3). The algal powder was ex-
tracted four times with absolute ethanol at room temperature. The extracts were pooled and evaporated to dryness at 35° to 40°C in a rotary evaporator. The residue was taken up in chloroform. The chloroform-soluble fraction was washed four times with acidic water (pH 4) in which the toxin is soluble and stable. These water fractions containing the toxin were then dried in air. The presence of the toxin was verified by its absorbance at 229 nm (3). This extract had an MLD of about 0.3 mg kg⁻¹ (intraperitoneal, mouse).

Two male, 6-week-old calves were given lyophilized algae in aqueous suspension by stomach tube directly into the reticulorumen. One, given 120 g (equal to 27 intraperitoneal mouse MLD's kg⁻¹) developed muscle fasciculations and loss of muscle coordination. The animal collapsed from respiratory arrest within 7 minutes. Intubation and artificial respiration restored normal heart rate, electrocardiogram, blood pressure, blood gases, and pH. Normal respiration failed to return within 6 hours. A second calf received a total of 8.75 MLD's in successive doses of 2.5, 2.5, 1.25, and 2.5 MLD's at 10-minute intervals. The effects were similar to those with the first calf, and respiratory collapse occurred 3 hours after administration of the final bolus. Artificial respiration was maintained for 30 hours with some intermittent but no permanent resumption of spontaneous respiration. Rats given lethal doses of toxin either orally or intraperitoneally show a latent period followed by twitches, gasping, and convulsions, with death occurring in 14 to 16 minutes. Rats were also maintained by artificial respiration for periods up to 8 hours, but again spontaneous respiration failed to return. Mice show signs similar to those of rats with death times of 4 to 5 minutes. The oral MLD of calves was estimated at 6 μg ml⁻¹ for up to 8 hours. This indicates that the toxin is not readily absorbed across the gill membranes.

Male mallard ducks given lyophilized algae in suspension either orally or intraperitoneally developed opisthotonus and muscular rigidity similar to that reported by Buttle and Zaimis (4) after the administration of decamethonium to chicks (Fig. 1). Opisthotonus has earlier been reported as a sign for pigeons given doses of algae from a mixed blue-green bloom that contained A. flos-aquae (5). Signs similar to opisthotonus have also been described in pigeons given a mixture of algae in which Anabaena was only a small component (6). The opisthotonus observed in ducks, because of the length of the neck in this animal, has some of the appearance of fowl botulism "limberneck" (7). It is, however, physiologically distinct and is not related.

Some tachyphylaxis (8) or resistance to successive sublethal doses of the toxic algal suspensions was observed in the responses of most species studied.
This was especially the case with the second calf which received sequential sublethal doses.

In anesthetized rats, intravenous injection of extract blocked responses of the anterior tibialis muscle to stimulation of the sciatic nerve (Fig. 2). The effect was not reversed by neostigmine. In vitro, on the rat phrenic nerve hemidiaphragm preparation, the extract blocked responses of the muscle to nerve stimulation. In anesthetized ducks, responses of the gastrocnemius muscle to stimulation of the sciatic nerve were blocked, and the muscle contracted (Fig. 3) in a manner similar to that reported for other avian species given depolarizing neuromuscular blocking agents. Blockade was not reversed by neostigmine but could be prevented by prior injection of d-tubocurarine. In chicks, injection of extract produced a typical depolarizing muscle relaxant syndrome (Fig. 4). On the frog rectus muscle, an extract of the algae gave a contractile response which was qualitatively similar to acetylcholine. d-Tubocurarine shifted dose-response lines of acetylcholine or the extract to the right in a parallel manner which indicated competitive inhibition. On the guinea pig ileum, large doses of extract caused a contraction that could be abolished by hexamethonium without affecting responses to acetylcholine.

It is concluded that lyophilized cells and extracts of the toxic strain A. flos-aquae NRC-44-1 contain a material which has many of the characteristics of a depolarizing neuromuscular blocking agent (9) that is very rapidly absorbed by the oral route. This toxin is considered to be the very fast death factor (VFDF) reported by Gorham et al. (10) as being produced by the parent strain NRC-44. The structure of the toxin, first described by Stavric and Gorham (3) as a tertiary amine, has since been deduced on chemical and spectroscopic grounds (11) and confirmed (12). An active fraction in crude synthetic material (13) shows similar toxicology and pharmacology to that of the lyophilized cells and extract.

WAYNE W. CARmichael
Department of Botany, University of Alberta, Edmonton, Alberta, Canada

References and Notes
14. Supported in part by a National Research Council of Canada grant. We thank T. Germaine, J. J. Tomenson, J. Bouvier, and R. Christopherson for coordination and assistance with the toxicology experiments.

29 July 1974: revised 30 September 1974

Glucagon: Role in the Hyperglycemia of Diabetes Mellitus

Abstract. Glucagon suppression by somatostatin reduces or abolishes hyperglycemia in dogs made insulin-deficient by somatostatin, alloxan, or total pancreatectomy. This suggests that the development of severe diabetic hyperglycemia requires the presence of glucagon, whether secreted by pancreatic or newly identified gastrointestinal A cells, as well as a lack of insulin. Glucagon suppression could improve therapeutic glucoregulation in diabetes.

The metabolic derangements of diabetic mellitus have traditionally been ascribed entirely to insulin deficiency. We propose that, in addition to lack of insulin, the presence of the insulin-opposing hormone glucagon is involved in the development of severe diabetic hyperglycemia. Two lines of evidence favor this. (i) Relative hyperglucagonemia has been found in every form of spontaneous (1) and experimental (2) diabetes examined thus far, including that produced by total pancreatectomy (3), a procedure which had been erroneously assumed to cause a deficiency of glucagon as well as of insulin. (ii) A simultaneous deficiency of both insulin and glucagon produced by the administration of somatostatin (4) does not give rise to hyperglycemia (5). The obvious physiologic and clinical importance of this question prompted us to study the role of glucagon in the pathogenesis of diabetic hyperglycemia.

Our results suggest that the development of diabetic hyperglycemia does, indeed, require the presence of glucagon. When both insulin and glucagon are suppressed to unmeasurable concentrations by somatostatin, hyperglycemia occurs only when glucagon concentrations are restored exogenously. As for the presence of hyperglycemia after pancreatectomy, we have confirmed the remarkable finding of Vranic et al., of Matsuyama and Foa, and of Mashter et al. (3) that glucagon is present in the plasma of totally depancreatectized dogs. Moreover, when release of glucagon after pancreatectomy is completely blocked by somatostatin, hyperglycemia is also blocked despite the absence of insulin. Glucagon of depancreatectized dogs, which mimics the secretory behavior of pancreatic glucagon with respect to its responses to arginine, insulin, and somatostatin infusion, probably originates in the gastrointestinal tract, where we find cells with granules indistinguishable from those in pancreatic A cells and a glucagon-like polypeptide immunometrically, biologically, and physicochemically similar to pancreatic glucagon. Finally, suppression of glucagon in alloxan-diabetic dogs results in rapid reduction of hyperglycemia to hypoglycemic concentrations, which suggests a potentially valuable new approach to the treatment of diabetes.

We studied insulin deficiency produced in dogs by somatostatin, by alloxan, and by total pancreatectomy. Pancreatectoglucagon was measured with the highly specific antiserum 30K (6). Gut glucagon-like immunoactivity (GLI), a polypeptide which differs immunochemically from pancreatic glu-